2'-hydroxy-4-methoxychalcone profile

ID Source	ID
PubMed CID	5331295
CHEMBL ID	241862
SCHEMBL ID	2807599
MeSH ID	M0099531

Synonym
MLS000438984 ,
smr000113000
2'-hydroxy-4-methoxychalcone
NCGC00090578-01
CHEMBL241862
AKOS001075364
(e)-1-(2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one
(2e)-1-(2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one
STK863551
1-(2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one
34000-29-8
2-propen-1-one, 1-(2-hydroxyphenyl)-3-(4-methoxyphenyl)-, (2e)-
HMS2206A21
nsc 19030
4-methoxy-2'-hydroxychalcone
nsc 91850
AB-0721
1-(2-hydroxyphenyl)-3-(4-methoxyphenyl)-2-propen-1-one
AB00075790-01
F0013-0895
bdbm76395
cid_5331295
(e)-1-(2-hydroxyphenyl)-3-(4-methoxyphenyl)-2-propen-1-one
J-501813
SCHEMBL2807599
NXBNYUSXDBHELA-DHZHZOJOSA-N
mfcd00016447
VU0008664-4
Q63398187
T72315
DTXSID701345759
trans-2'-hydroxy-4-methoxychalcone
Z57101040

Excerpt	Reference	Relevance
"A total of 30 chalcone analogues was synthesized via a base catalyzed Claisen Schmidt condensation and screened for their in vitro antibacterial activity against Methicillin-sensitive Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus (MRSA) alone or in combination with non beta-lactam antibiotics namely ciprofloxacin, chloramphenicol, erythromycin, vancomycin, doxycycline and gentamicin."	( Synthesis and anti Methicillin resistant Staphylococcus aureus activity of substituted chalcones alone and in combination with non-beta-lactam antibiotics. Do, TH; Huynh, TN; Ngo, TD; Thai, KM; Tran, CD; Tran, NC; Tran, TD, 2012)	0.38

Protein Targets (32)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	63.0957	0.6310	35.7641	100.0000	AID504339
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	35.4813	5.6234	17.2929	31.6228	AID485281
Luciferase	Photinus pyralis (common eastern firefly)	Potency	0.2685	0.0072	15.7588	89.3584	AID588342
phosphopantetheinyl transferase	Bacillus subtilis	Potency	70.7946	0.1413	37.9142	100.0000	AID1490
ATAD5 protein, partial	Homo sapiens (human)	Potency	16.3601	0.0041	10.8903	31.5287	AID504466; AID504467
TDP1 protein	Homo sapiens (human)	Potency	15.4706	0.0008	11.3822	44.6684	AID686978; AID686979
Microtubule-associated protein tau	Homo sapiens (human)	Potency	8.4719	0.1800	13.5574	39.8107	AID1460
nonstructural protein 1	Influenza A virus (A/WSN/1933(H1N1))	Potency	10.0000	0.2818	9.7212	35.4813	AID2326
67.9K protein	Vaccinia virus	Potency	22.3872	0.0001	8.4406	100.0000	AID720579
luciferase	Photuris pensylvanica (Pennsylania firefly)	Potency	11.2202	0.8913	10.4328	20.5750	AID1379
bromodomain adjacent to zinc finger domain 2B	Homo sapiens (human)	Potency	12.5893	0.7079	36.9043	89.1251	AID504333
P53	Homo sapiens (human)	Potency	79.4328	0.0731	9.6858	31.6228	AID504706
pyruvate kinase	Leishmania mexicana mexicana	Potency	25.1189	0.3981	13.7447	31.6228	AID1721; AID1722
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	44.6684	0.0355	20.9770	89.1251	AID504332
cytochrome P450 2D6 isoform 1	Homo sapiens (human)	Potency	3.1623	0.0020	7.5337	39.8107	AID891
cytochrome P450 2C19 precursor	Homo sapiens (human)	Potency	1.2589	0.0025	5.8400	31.6228	AID899
cytochrome P450 2C9 precursor	Homo sapiens (human)	Potency	3.9811	0.0063	6.9043	39.8107	AID883
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	56.2341	0.3548	28.0659	89.1251	AID504847
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	29.0929	0.0041	9.9848	25.9290	AID504444
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	39.8107	0.0079	8.2332	1,122.0200	AID2551
geminin	Homo sapiens (human)	Potency	0.1032	0.0046	11.3741	33.4983	AID624297
Endothelin receptor type B	Rattus norvegicus (Norway rat)	Potency	25.1189	0.5623	15.1609	31.6228	AID1721
Endothelin-1 receptor	Rattus norvegicus (Norway rat)	Potency	25.1189	0.5623	15.1609	31.6228	AID1721
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	Potency	3.9811	0.0063	8.2350	39.8107	AID883
TAR DNA-binding protein 43	Homo sapiens (human)	Potency	19.9526	1.7783	16.2081	35.4813	AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
SUMO-1-specific protease	Homo sapiens (human)	IC50 (µMol)	6.0000	0.8050	19.3461	87.7000	AID488921
SUMO1/sentrin specific peptidase 7	Homo sapiens (human)	IC50 (µMol)	3.9300	1.6400	7.2648	23.9000	AID488904
caspase-3 isoform a preproprotein	Homo sapiens (human)	IC50 (µMol)	23.1000	0.0256	20.3235	74.3000	AID488901
sentrin-specific protease 8	Homo sapiens (human)	IC50 (µMol)	10.6000	0.0408	18.9292	94.8000	AID488903
Acetylcholinesterase	Tetronarce californica (Pacific electric ray)	IC50 (µMol)	92.9000	0.0057	0.4285	5.1200	AID1799680
Shiga toxin subunit A	Shigella dysenteriae	Ki	9.9300	9.9300	9.9300	9.9300	AID1324538
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Process	via Protein(s)	Taxonomy
negative regulation of protein phosphorylation	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA processing	TAR DNA-binding protein 43	Homo sapiens (human)
RNA splicing	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of protein stability	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of insulin secretion	TAR DNA-binding protein 43	Homo sapiens (human)
response to endoplasmic reticulum stress	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of protein import into nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of circadian rhythm	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of apoptotic process	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation by host of viral transcription	TAR DNA-binding protein 43	Homo sapiens (human)
rhythmic process	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of cell cycle	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA destabilization	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear inner membrane organization	TAR DNA-binding protein 43	Homo sapiens (human)
amyloid fibril formation	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Process	via Protein(s)	Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Process	via Protein(s)	Taxonomy
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (66)

Assay ID	Title	Year	Journal	Article
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID513962	Induction of quinone reductase activity in rat liver at 22.5 mg/kg, po qd	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Identification of chalcones as in vivo liver monofunctional phase II enzymes inducers.
AID1324538	Inhibition of Shigella dysenteriae type 1 Shiga toxin A subunit assessed as change in transition temperature by SYPRO orange dye based fluorescence-based thermal shift assay	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	In Silico Discovery and Validation of Amide Based Small Molecule Targeting the Enzymatic Site of Shiga Toxin.
AID1167300	Antioxidant activity assessed as DPPH radical scavenging activity incubated at room temperature for 20 mins by UV-visible spectrophotometry	2014	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21	Design, synthesis and exploring the quantitative structure-activity relationship of some antioxidant flavonoid analogues.
AID452853	Antioxidant activity assessed as hydrogen peroxide scavenging activity by peroxyoxalate chemiluminescent method	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Natural and synthetic 2'-hydroxy-chalcones and aurones: synthesis, characterization and evaluation of the antioxidant and soybean lipoxygenase inhibitory activity.
AID452850	Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 60 mins	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Natural and synthetic 2'-hydroxy-chalcones and aurones: synthesis, characterization and evaluation of the antioxidant and soybean lipoxygenase inhibitory activity.
AID295381	Cytotoxicity against human MCF7 cells ATCC HTB38 in aerobic condition assessed as survival at 100 uM by sulforhodamine assay	2007	Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10	Synthetic chalcones, flavanones, and flavones as antitumoral agents: biological evaluation and structure-activity relationships.
AID452848	Antioxidant activity assessed as DPPH radical scavenging activity at 50 uM after 60 mins	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Natural and synthetic 2'-hydroxy-chalcones and aurones: synthesis, characterization and evaluation of the antioxidant and soybean lipoxygenase inhibitory activity.
AID1186725	Cytotoxicity against human HL60 cells by MTT assay	2014	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17	Cytotoxic activity of substituted chalcones in terms of molecular electronic properties.
AID638551	Inhibition of MRP1 overexpressed in human 2008 MRP1 cells assessed as calcein AM accumulation at 10 uM by fluorimetry	2012	Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1	Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.
AID1324539	Cytotoxicity against African green monkey Vero cells incubated for 24 hrs by neutral red uptake assay	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	In Silico Discovery and Validation of Amide Based Small Molecule Targeting the Enzymatic Site of Shiga Toxin.
AID513976	Toxicity in Sprague-Dawley rat assessed as glutamic-pyruvate level at 250 mg/kg, po (RVb = 22.8 +/-13.2 U/L)	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Identification of chalcones as in vivo liver monofunctional phase II enzymes inducers.
AID513974	Toxicity in Sprague-Dawley rat assessed as leucocyte level at 250 mg/kg, po (RVb = 200 +/- 1500 /uL)	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Identification of chalcones as in vivo liver monofunctional phase II enzymes inducers.
AID513957	Cytotoxicity against human MCF7 cells	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Identification of chalcones as in vivo liver monofunctional phase II enzymes inducers.
AID1752772	Inhibition of Schistosoma mansoni ATPDase1 incubated for 30 mins	2020	RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4	Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?
AID513963	Induction glutathione-S-transferase activity in rat liver at 22.5 mg/kg, po qd	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Identification of chalcones as in vivo liver monofunctional phase II enzymes inducers.
AID1186727	Cytotoxicity against human WM115 cells by MTT assay	2014	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17	Cytotoxic activity of substituted chalcones in terms of molecular electronic properties.
AID513977	Toxicity in Sprague-Dawley rat assessed as glutamic-oxalate transaminase level at 250 mg/kg, po (RVb = 71.4 +/- 7.8 U/L)	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Identification of chalcones as in vivo liver monofunctional phase II enzymes inducers.
AID638478	Inhibition of human BCRP expressed in MDCK2 cells assessed as Hoechst 33342 accumulation preincubated for 30 mins by fluorimetry	2012	Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1	Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.
AID759072	Cytotoxicity against human HCT116 cells assessed as cell viability at 15 uM after 48 hrs by MTT assay relative to control	2013	European journal of medicinal chemistry, Jul, Volume: 65	Superior anticancer activity of halogenated chalcones and flavonols over the natural flavonol quercetin.
AID295385	Growth inhibition of HT29 cells by sulforhodamine assay	2007	Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10	Synthetic chalcones, flavanones, and flavones as antitumoral agents: biological evaluation and structure-activity relationships.
AID1698235	Effect on cell viability in human neutrophils assessed as decrease in cell viability at 25 uM after 1 hr by Propidium staining based flow cytometric analysis	2020	Journal of natural products, 10-23, Volume: 83, Issue:10	Chalcones as Modulators of Neutrophil Oxidative Burst under Physiological and High Glucose Conditions.
AID513975	Toxicity in Sprague-Dawley rat assessed as haemoglobin level at 250 mg/kg, po (RVb = 15.1 +/- 4.1 g/L)	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Identification of chalcones as in vivo liver monofunctional phase II enzymes inducers.
AID670957	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 at 256 ug/ml after 24 hrs by disc diffusion method	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Synthesis and anti Methicillin resistant Staphylococcus aureus activity of substituted chalcones alone and in combination with non-beta-lactam antibiotics.
AID1076733	Growth inhibition of cisplatin-resistant human A2780cis cells after 7 days by crystal violet staining based clonogenic assay	2014	Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6	Polyphenols bearing cinnamaldehyde scaffold showing cell growth inhibitory effects on the cisplatin-resistant A2780/Cis ovarian cancer cells.
AID452849	Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 20 mins	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Natural and synthetic 2'-hydroxy-chalcones and aurones: synthesis, characterization and evaluation of the antioxidant and soybean lipoxygenase inhibitory activity.
AID295383	Growth inhibition of TK10 cells by sulforhodamine assay	2007	Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10	Synthetic chalcones, flavanones, and flavones as antitumoral agents: biological evaluation and structure-activity relationships.
AID513964	Induction glutathione-CYP1A1 in rat liver at 22.5 mg/kg, po qd by EROD assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Identification of chalcones as in vivo liver monofunctional phase II enzymes inducers.
AID295384	Growth inhibition of MCF7 cells by sulforhodamine assay	2007	Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10	Synthetic chalcones, flavanones, and flavones as antitumoral agents: biological evaluation and structure-activity relationships.
AID452847	Antioxidant activity assessed as DPPH radical scavenging activity at 50 uM after 20 mins	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Natural and synthetic 2'-hydroxy-chalcones and aurones: synthesis, characterization and evaluation of the antioxidant and soybean lipoxygenase inhibitory activity.
AID661075	Antidiabetic activity in mouse 3T3L1 cells assessed as decrease in glucose consumption from cell culture medium using 450 mg/dL D-glucose at 30 ug/mL after 24 hrs (Rvb = 310 +/- 4 mg/dl)	2012	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12	Synthesis of chalcone derivatives as potential anti-diabetic agents.
AID452851	Antioxidant activity assessed as superoxide anion radical scavenging activity at 10 uM	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Natural and synthetic 2'-hydroxy-chalcones and aurones: synthesis, characterization and evaluation of the antioxidant and soybean lipoxygenase inhibitory activity.
AID295382	Cytotoxicity against human HT29 cells ATCC HTB38 in aerobic condition assessed as survival at 100 uM by sulforhodamine assay	2007	Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10	Synthetic chalcones, flavanones, and flavones as antitumoral agents: biological evaluation and structure-activity relationships.
AID418269	Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 10 uM by MTT assay	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study.
AID452854	Antioxidant activity assessed as inhibition of AAPH-induced lipid peroxidation at 10 uM by uV spectrophotometry	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Natural and synthetic 2'-hydroxy-chalcones and aurones: synthesis, characterization and evaluation of the antioxidant and soybean lipoxygenase inhibitory activity.
AID1737236	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells at 10 uM measured after 24 hrs by Griess reagent based assay relative to control	2020	European journal of medicinal chemistry, May-01, Volume: 193	Development of a novel nitric oxide (NO) production inhibitor with potential therapeutic effect on chronic inflammation.
AID418267	Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW264.7 cells at 10 uM by enzyme immunoassay	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study.
AID452852	Antioxidant activity assessed as hydroxyl radical scavenging activity at 100 uM	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Natural and synthetic 2'-hydroxy-chalcones and aurones: synthesis, characterization and evaluation of the antioxidant and soybean lipoxygenase inhibitory activity.
AID295386	Growth inhibition of HK2 cells by sulforhodamine assay	2007	Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10	Synthetic chalcones, flavanones, and flavones as antitumoral agents: biological evaluation and structure-activity relationships.
AID513959	Cytotoxicity against human HT-29 cells	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Identification of chalcones as in vivo liver monofunctional phase II enzymes inducers.
AID1698241	Inhibition of PMA-induce ROS/RNS generation in human neutrophils at 25 uM measured up to 30 mins in presence of 5.5 mM glucose by luminol-amplified chemiluminescence method relative to control	2020	Journal of natural products, 10-23, Volume: 83, Issue:10	Chalcones as Modulators of Neutrophil Oxidative Burst under Physiological and High Glucose Conditions.
AID670950	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 at 256 ug/ml after 24 hrs by disc diffusion method	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Synthesis and anti Methicillin resistant Staphylococcus aureus activity of substituted chalcones alone and in combination with non-beta-lactam antibiotics.
AID1324537	Inhibition of Shigella dysenteriae type 1 Shiga toxin A subunit	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	In Silico Discovery and Validation of Amide Based Small Molecule Targeting the Enzymatic Site of Shiga Toxin.
AID1186726	Cytotoxicity against human NALM6 cells by MTT assay	2014	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17	Cytotoxic activity of substituted chalcones in terms of molecular electronic properties.
AID513978	Toxicity in Sprague-Dawley rat assessed as change in body weight at 250 mg/kg, po	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Identification of chalcones as in vivo liver monofunctional phase II enzymes inducers.
AID513958	Cytotoxicity against human TK10 cells	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Identification of chalcones as in vivo liver monofunctional phase II enzymes inducers.
AID295380	Cytotoxicity against human TK10 cells in aerobic condition assessed as survival at 100 uM by sulforhodamine assay	2007	Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10	Synthetic chalcones, flavanones, and flavones as antitumoral agents: biological evaluation and structure-activity relationships.
AID638550	Inhibition of MDR1 in human A2780adr cells assessed as calcein AM accumulation at 10 uM by fluorimetry	2012	Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1	Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.
AID1752771	Antischistosomal activity against Schistosoma mansoni BH infected in Balb/c mouse assessed as reduction in worm burden at 400 mg/kg, po measurement after 2 weeks	2020	RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4	Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?
AID1698246	Inhibition of PMA-induce ROS/RNS generation in human neutrophils at 25 uM measured up to 30 mins in presence of 30 mM glucose by luminol-amplified chemiluminescence method relative to control	2020	Journal of natural products, 10-23, Volume: 83, Issue:10	Chalcones as Modulators of Neutrophil Oxidative Burst under Physiological and High Glucose Conditions.
AID452856	Inhibition of soybean 5-lipoxygenase at 100 uM by UV-absorbance based enzyme assay	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Natural and synthetic 2'-hydroxy-chalcones and aurones: synthesis, characterization and evaluation of the antioxidant and soybean lipoxygenase inhibitory activity.
AID638477	Inhibition of BCRP in human MCF7/MX cells assessed as Hoechst 33342 accumulation preincubated for 30 mins by Fluorometry	2012	Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1	Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1799680	Enzyme Inhibition Assay from Article 10.1080/14756360400015231: \\Synthesis and inhibitory potential towards acetylcholinesterase, butyrylcholinesterase and lipoxygenase of some variably substituted chalcones.\\	2005	Journal of enzyme inhibition and medicinal chemistry, Feb, Volume: 20, Issue:1	Synthesis and inhibitory potential towards acetylcholinesterase, butyrylcholinesterase and lipoxygenase of some variably substituted chalcones.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (3.70)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (22.22)	29.6817
2010's	14 (51.85)	24.3611
2020's	6 (22.22)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (3.70%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	26 (96.30%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
salicylic acid Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).	2.1	1	monohydroxybenzoic acid	algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite
gallic acid gallate : A trihydroxybenzoate that is the conjugate base of gallic acid.	2.1	1	trihydroxybenzoic acid	antineoplastic agent; antioxidant; apoptosis inducer; astringent; cyclooxygenase 2 inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; geroprotector; human xenobiotic metabolite; plant metabolite
4'-bromoflavone 4'-bromoflavone: structure in first source	2.45	2
4-phenyl-3-furoxancarbonitrile 4-phenyl-3-furoxancarbonitrile: structure given in first source. 4-phenyl-3-furoxancarbonitrile : A 1,2,5-oxadiazole substituted by an oxido, cyano and phenyl groups at positions 2, 3 and 4, respectively. It is a vasodilator and inhibitor of platelet aggregation.	3.35	1	1,2,5-oxadiazole; benzenes; N-oxide; nitrile	geroprotector; nitric oxide donor; platelet aggregation inhibitor; soluble guanylate cyclase activator; vasodilator agent
theophylline [no description available]	1.96	1	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
berberine [no description available]	2.07	1	alkaloid antibiotic; berberine alkaloid; botanical anti-fungal agent; organic heteropentacyclic compound	antilipemic drug; antineoplastic agent; antioxidant; EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor; EC 1.21.3.3 (reticuline oxidase) inhibitor; EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.1.4 (phospholipase A2) inhibitor; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; hypoglycemic agent; metabolite; potassium channel blocker
cgs 15943 9-chloro-2-(2-furyl)-(1,2,4)triazolo(1,5-c)quinazolin-5-imine: non-xanthine triazoloquinazoline adenosine antagonist. CGS 15943 : A member of the class of triazoloquinazolines that is [1,2,4]triazolo[1,5-c]quinazoline substited at positions 2, 5 and 9 by furan-2-yl, amino and chloro groups respectively. A potent antagonist at adenosine A1 and adenosine A2A receptors.	3.35	1	aromatic amine; biaryl; furans; organochlorine compound; primary amino compound; quinazolines; triazoloquinazoline	adenosine A1 receptor antagonist; adenosine A2A receptor antagonist; antineoplastic agent; central nervous system stimulant
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	2.07	1	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
cl 387785 CL 387785: structure in first source. N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide : A member of the class of quinazolines that is 4,6-diaminoquinazoine in which the one of the hydrogens attached to the amino group at position 4 has been replaced by a m-bromophenyl group while one of the hydrogens attached to the amino group at position 6 has been replaced by a but-2-ynoyl group.	3.35	1	bromobenzenes; quinazolines; secondary carboxamide; ynamide	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist
dyphylline Dyphylline: A THEOPHYLLINE derivative with broncho- and vasodilator properties. It is used in the treatment of asthma, cardiac dyspnea, and bronchitis.. dyphylline : An oxopurine that is theophylline bearing a 2,3-dihydroxypropyl group at the 7 position. It has broncho- and vasodilator properties, and is used in the treatment of asthma, cardiac dyspnea, and bronchitis. It is also an ingredient in preparations that have been promoted for coughs.	1.96	1	oxopurine; propane-1,2-diols	bronchodilator agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; muscle relaxant; vasodilator agent
masoprocol nordihydroguaretic acid: antioxidant compound found in the creosote bush (Larrea tridentata)	2.05	1	catechols; lignan; tetrol	antioxidant; ferroptosis inhibitor; geroprotector; plant metabolite
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source. NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2.	2.05	1	aromatic ether; C-nitro compound; sulfonamide	antineoplastic agent; cyclooxygenase 2 inhibitor
oxamniquine Oxamniquine: An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs. (From Martindale, The Extra Pharmacopoeia, 31st ed, p121). oxamniquine : A racemate comprising equimolar amounts of (R)- and (S)-oxamniquine. An anthelmintic, it is administered orally for the treatment of schistomiasis caused by Schistosoma mansoni (but not by other Schistosoma species); intramuscular administration is no longer used as it causes severe pain at the injection site.. {2-[(isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl}methanol : A member of the class of quinolines that is 1,2,3,4-tetrahydroquinoline which is substituted at positions 2, 6, and 7 by (isopropylamino)methyl, hydroxymethyl, and nitro groups, respectively.	3.35	1	aromatic primary alcohol; C-nitro compound; quinolines; secondary amino compound
pioglitazone Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.	2.48	2	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
praziquantel azinox: Russian drug	3.35	1	isoquinolines
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	2.07	1	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
adenosine monophosphate Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.	2.13	1	adenosine 5'-phosphate; purine ribonucleoside 5'-monophosphate	adenosine A1 receptor agonist; cofactor; EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.11 (fructose-bisphosphatase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
ethane Ethane: A two carbon alkane with the formula H3C-CH3.. ethane : An alkane comprising of two carbon atoms.	2.41	1	alkane; gas molecular entity	plant metabolite; refrigerant
salicylaldehyde o-hydroxybenzaldehyde: structure in first source	2.1	1	hydroxybenzaldehyde	nematicide; plant metabolite
furaldehyde Furaldehyde: A heterocyclic compound consisting of a furan where the hydrogen at position 2 is substituted by a formyl group.. furfural : An aldehyde that is furan with the hydrogen at position 2 substituted by a formyl group.	2.1	1	aldehyde; furans	Maillard reaction product; metabolite
2'-hydroxyacetophenone 2-acetylphenol : A monohydroxyacetophenone that is acetophenone in which one of the hydrogens ortho to the acetyl group has been replaced by a hydroxy group.	2.1	1	monohydroxyacetophenone; phenols	flavouring agent
piperonal piperonal: has been used as a pediculicide; structure. piperonal : An arenecarbaldehyde that is 1,3-benzodioxole substituted by a formyl substituent at position 5. It has been isolated from Piper nigrum.	2.1	1	arenecarbaldehyde; benzodioxoles	fragrance; insect repellent; plant metabolite
3-tert-butyl-4-hydroxyanisole 3-tert-butyl-4-hydroxyanisole : An aromatic ether that is 4-methoxyphenol in which one of the hydrogens ortho- to the phenolic hydroxy group is replaced by a tert-butyl group.	2.1	1	aromatic ether; phenols	antioxidant; human xenobiotic metabolite
2-aminopurine 2-Aminopurine: A purine that is an isomer of ADENINE (6-aminopurine).. aminopurine : Any purine having at least one amino substituent.. 2-aminopurine : The parent compound of the 2-aminopurines, comprising a purine core carrying an amino substituent at the 2-position.	2.13	1	2-aminopurines; nucleobase analogue	antimetabolite
flavanone flavanone: RN given refers to cpd with unspecified isomeric designation; structure in first source. flavanone : The simplest member of the class of flavanones that consists of flavan bearing an oxo substituent at position 4.	2.46	2	flavanones
flavone flavone: RN given refers to unlabeled cpd; structure given in first source. flavone : The simplest member of the class of flavones that consists of 4H-chromen-4-one bearing a phenyl substituent at position 2.	2.75	3	flavones	metabolite; nematicide
3-hydroxyflavone 3-hydroxyflavone: structure given in first source. flavonol : A monohydroxyflavone that is the 3-hydroxy derivative of flavone.	2.49	2	flavonols; monohydroxyflavone
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	2.07	1	cyclic ketone; erythromycin
vancomycin Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.	2.07	1	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
2,6-diaminopurine 9H-purine-2,6-diamine : A member of the class of 2,6-diaminopurines that is 9H-purine in which the hydrogens at positions 2 and 6 are replaced by amino groups.	2.13	1	2,6-diaminopurines; primary amino compound	antineoplastic agent
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid [no description available]	2.47	2	chromanol; monocarboxylic acid; phenols	antioxidant; ferroptosis inhibitor; neuroprotective agent; radical scavenger; Wnt signalling inhibitor
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	2.13	1	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
dihydrochalcone dihydrochalcone : A member of the class of dihydrochalcones that is acetophenone in which one of the hydrogens of the methyl group is replaced by a benzyl group.	2.41	1	dihydrochalcones	plant metabolite
pinocembrin pinocembrin : A dihydroxyflavanone in which the two hydroxy groups are located at positions 5 and 7. A natural product found in Piper sarmentosum and Cryptocarya chartacea.	2.1	1	(2S)-flavan-4-one; dihydroxyflavanone	antineoplastic agent; antioxidant; metabolite; neuroprotective agent; vasodilator agent
4-chromanone [no description available]	2.1	1	chromones
4-aminopyrimidine [no description available]	2.13	1	aminopyrimidine
8-azaadenine 8-azaadenine: xanthine oxidase inhibitor. 8-azaadenine : A triazolopyrimidine that is [1,2,3]triazolo[4,5-d]pyrimidine bearing an amino substituent at position 7.	2.13	1	aromatic amine; nucleobase analogue; triazolopyrimidines	EC 1.17.3.2 (xanthine oxidase) inhibitor; Mycoplasma genitalium metabolite
n-(hydroxymethyl)carbazole N-(hydroxymethyl)carbazole: structure given in first source	2.1	1
4'-methoxyflavone 4'-methoxyflavone: from seeds of Psoralea corylifolia (Fabaceae); structure in first source	2.46	2	ether; flavonoids
rosiglitazone [no description available]	2.48	2	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug
mmv665852 MMV665852: an antischistosomal agent	3.35	1
karanjin karanjin: structure given in first source	2.1	1	extended flavonoid
4'-methoxyflavanone 4'-methoxyflavanone : The parent member of the class of 4'-methoxyflavanones that is flavanone which is substituted by a methoxy group at the 4'-position.	2.45	2	4'-methoxyflavanones
gr 127935 GR 127935: a 5-HT 1D receptor antagonist. GR 127935 : A member of the class of benzamides obtained by formal condensation of the carboxy group of 2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxylic acid and the anilino group of 4-methoxy-3-(4-methylpiperazin-1-yl)aniline. Potent and selective 5-HT1B/1D receptor antagonist (pKi values are 8.5 for both guinea pig 5-HT1D and rat 5-HT1B receptors). Displays > 100-fold selectivity over 5HT1A, 5-HT2A, 5-HT2C receptors and other receptor types. Centrally active following oral administration.	3.35	1	1,2,4-oxadiazole; benzamides; N-alkylpiperazine; N-arylpiperazine
parthenolide [no description available]	3.35	1	germacranolide
4'-chloroflavone 4'-chloroflavone: structure given in first source	2.46	2
e-z cinnamic acid cinnamic acid : A monocarboxylic acid that consists of acrylic acid bearing a phenyl substituent at the 3-position. It is found in Cinnamomum cassia.. trans-cinnamic acid : The E (trans) isomer of cinnamic acid	2.1	1	cinnamic acid	plant metabolite
clindamycin Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.	2.07	1
gw 3965 GW 3965: a liver X receptor ligand	3.35	1	diarylmethane
cinnamaldehyde 3-phenylprop-2-enal : A member of the class of cinnamaldehydes that is prop-2-enal in which a hydrogen at position 3 has been replaced by a phenyl group. The configuration of the double bond is not specified; the name "cinnamaldehyde" is widely used to refer to the E (trans) isomer.. (E)-cinnamaldehyde : The E (trans) stereoisomer of cinnamaldehyde, the parent of the class of cinnamaldehydes.	2.1	1	3-phenylprop-2-enal; cinnamaldehydes	antifungal agent; EC 4.3.1.24 (phenylalanine ammonia-lyase) inhibitor; flavouring agent; hypoglycemic agent; plant metabolite; sensitiser; vasodilator agent
trans-4-coumaric acid hydroxycinnamic acid : Any member of the class of cinnamic acids carrying one or more hydroxy substituents.. trans-4-coumaric acid : The trans-isomer of 4-coumaric acid.. 4-coumaric acid : A coumaric acid in which the hydroxy substituent is located at C-4 of the phenyl ring.	2.1	1	4-coumaric acid	food component; mouse metabolite; plant metabolite
benzylideneacetone benzylideneacetone: RN given refers to cpd without isomeric; structure in Merck Index, 9th ed, #1153. trans-benzylideneacetone : The trans-isomer of benzylideneacetone. It acts as an inhibitor of the enzyme phospholipase A2 (EC 3.1.1.4) of insects like diamond back moth.. benzylideneacetone : An enone in which a phenyl ring is attached to the beta-carbon atom of but-3-en-2-one. Although both cis- and trans-isomers are possible for the alpha,beta-unsaturated ketone, only the trans-isomer is observed.	2.1	1	benzylideneacetone	bacterial metabolite; EC 3.1.1.4 (phospholipase A2) inhibitor; flavouring agent; fragrance
chalcone trans-chalcone : The trans-isomer of chalcone.	3.66	9	chalcone	EC 3.2.1.1 (alpha-amylase) inhibitor
2'-hydroxychalcone 2'-hydroxychalcone : A member of the class of chalcones that is trans-chalcone substituted by a hydroxy group at position 2'.	3.86	11	chalcones; phenols	anti-inflammatory agent
2,2'-dihydroxychalcone 2,2'-dihydroxychalcone: an antineoplastic agent; structure in first source	2.53	2
cardamonin cardamonin: found in Zingiberaceae; structure in first source	3.35	1	chalcones
3',4',5'-trimethoxyflavonol 3',4',5'-trimethoxyflavonol: has anticarcinogenic activity; structure in first source	2.08	1
caffeic acid trans-caffeic acid : The trans-isomer of caffeic acid.	2.05	1	caffeic acid	geroprotector; mouse metabolite
stattic [no description available]	3.35	1	1-benzothiophenes; C-nitro compound; sulfone	antineoplastic agent; radiosensitizing agent; STAT3 inhibitor
enpiroline enpiroline: structure	3.35	1
rs 17053 [no description available]	3.35	1	indoles
quercetin [no description available]	2.77	3	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
luteolin [no description available]	2.25	1	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
beta carotene beta Carotene: A carotenoid that is a precursor of VITAMIN A. Beta carotene is administered to reduce the severity of photosensitivity reactions in patients with erythropoietic protoporphyria (PORPHYRIA, ERYTHROPOIETIC).. provitamin A : A provitamin that can be converted into vitamin A by enzymes from animal tissues.	2.05	1	carotenoid beta-end derivative; cyclic carotene	antioxidant; biological pigment; cofactor; ferroptosis inhibitor; human metabolite; mouse metabolite; plant metabolite; provitamin A
aureusidin aureusidin: structure in first source. aureusidin : A hydroxyaurone that is aurone substituted by hydroxy groups at positions 4, 6, 3' and 4' respectively.	2.05	1	hydroxyaurone	plant metabolite
isobavachalcone isobavachalcone: RN given for (E)-isomer; structure in first source. isobavachalcone : A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 4, 2' and 4' and a prenyl group at position 3'.	2.25	1	chalcones; polyphenol	antibacterial agent; metabolite; platelet aggregation inhibitor
galangin 5,7-dihydroxyflavonol: antimicrobial from the twigs of Populus nigra x Populus deltoides; structure in first source. galangin : A 7-hydroxyflavonol with additional hydroxy groups at positions 3 and 5 respectively; a growth inhibitor of breast tumor cells.	2.1	1	7-hydroxyflavonol; trihydroxyflavone	antimicrobial agent; EC 3.1.1.3 (triacylglycerol lipase) inhibitor; plant metabolite
wogonin wogonin: structure in first source. wogonin : A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-8.	2.05	1	dihydroxyflavone; monomethoxyflavone	angiogenesis inhibitor; antineoplastic agent; cyclooxygenase 2 inhibitor; plant metabolite
4-hydroxychalcone 4-hydroxychalcone: structure in first source. 4-hydroxychalcone : A member of the class of chalcones that is trans-chalcone substituted by a hydroxy group at position 4.	2.99	4	chalcones; phenols	antihypertensive agent; plant metabolite
6-methylpurine 6-methylpurine : Purine bearing a methyl substituent at position 6.	2.13	1	purines	EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor
licochalcone a licochalcone A: has both anti-inflammatory and antineoplastic activities; structure given in first source; isolated from root of Glycyrrhiza inflata; RN given refers to (E)-isomer	3.35	1	chalcones
flavokawain a flavokawain A: from kava extract, induces apoptosis in bladder cancer cells; structure in first source	3.19	5	chalcones
flavokawain b flavokawain B: from Piper methysticum Forst (Kava Kava) roots; structure in first source. flavokawain B : A member of the class of chalcones that consists of trans-chalcone substituted by hydroxy group at positions 2' and methoxy groups at positions 4' and 6'. Isolated from Piper methysticum and Piper rusbyi, it exhibits antileishmanial, anti-inflammatory and antineoplastic activities.	2.25	1	chalcones; dimethoxybenzene; phenols	anti-inflammatory agent; antileishmanial agent; antineoplastic agent; apoptosis inducer; metabolite
Isoliquiritigenin 4,4'-dimethyl ether [no description available]	2.8	3	chalcones
2',4'-dihydroxychalcone 2',4'-dihydroxychalcone: RN given refers to (E)-isomer; RN for cpd without isomeric designation not available 6/89; structure given in first source	2.98	4
4-chlorochalcone 4-chlorochalcone : A member of the class of chalcones that is trans-chalcone substituted by a chloro group at position 4.	2.77	3	chalcones; monochlorobenzenes
aldosterone dehydrodiisoeugenol: an isoeugenol dimer, inhibits lipopolysaccharide-stimulated nuclear factor kappa B activation and cyclooxygenase-2 expression in macrophages; structure in first source	3.35	1
4'-chloroaurone 4'-chloroaurone: aurones from marine brown alga Spatoglossum variabile; structure in first source	2.05	1
Crotaoprostrin [no description available]	3.19	5	chalcones
2',5'-dihydroxychalcone 2',5'-dihydroxychalcone: structure given in first source	2.1	1	chalcones
4-hydroxylonchocarpin 4-hydroxylonchocarpin: structure in first source	2.25	1
2-chloro-4',6'-dimethoxy-2'-hydroxychalcone 2-chloro-4',6'-dimethoxy-2'-hydroxychalcone: induces glutathione biosynthesis; structure in first source	2.07	1
metochalcone metochalcone: structure	2.07	1
flavokawain C flavokawain C: antineoplastic from roots of Kava (Piper methysticum Forst); structure in first source	2.25	1	chalcones
broussochalcone a broussochalcone A: RN given for (E)-isomer; inhibits neutrophil respiratory burst; structure in first source	2.25	1
ekb 569 EKB 569: an EGF receptor kinase inhibitor	3.35	1	aminoquinoline; monocarboxylic acid amide; monochlorobenzenes; nitrile	protein kinase inhibitor
ispinesib [no description available]	3.35	1	benzamides
gentamicin sulfate [no description available]	2.07	1
1,2,6,7-tetraoxaspiro(7.11)nonadecane 1,2,6,7-tetraoxaspiro(7.11)nonadecane: structure in first source	3.35	1
2,4,2',4'-Tetrahydroxychalcone [no description available]	2.25	1	chalcones
sd-208 [no description available]	3.35	1
ko 143 [no description available]	2.07	1	beta-carbolines; tert-butyl ester
Kanzonol B [no description available]	2.25	1	chalcones
bi 2536 [no description available]	3.35	1
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	2.1	1	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
bms-833923 BMS-833923: an Smo inhibitor	3.35	1
guanine [no description available]	2.13	1	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	2.13	1	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger

Condition	Relationship Strength	Studies
Abnormalities, Autosome [description not available]	2.03	1
Innate Inflammatory Response [description not available]	3.2	5
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	8.2	5
Cancer of Liver [description not available]	2.05	1
Liver Neoplasms Tumors or cancer of the LIVER.	2.05	1
Breast Cancer [description not available]	2.07	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.07	1
Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.	2.07	1
Cancer of Ovary [description not available]	2.1	1
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.1	1
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1
Chronic Illness [description not available]	2.25	1
Polyarthritis [description not available]	2.25	1
Arthritis Acute or chronic inflammation of JOINTS.	2.25	1
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2.25	1
Atrophy, Muscle [description not available]	2.41	1
Muscular Atrophy Derangement in size and number of muscle fibers occurring with aging, reduction in blood supply, or following immobilization, prolonged weightlessness, malnutrition, and particularly in denervation.	2.41	1
Atherogenesis [description not available]	2.07	1
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	2.07	1
Arteriosclerosis Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.	1.96	1

2'-hydroxy-4-methoxychalcone

Cross-References

Synonyms (33)

Research Excerpts

Compound-Compound Interactions

Protein Targets (32)

Potency Measurements

Inhibition Measurements

Biological Processes (18)

Molecular Functions (10)

Ceullar Components (9)

Bioassays (66)

Research

Studies (27)

Market Indicators

Research Demand Index: 18.77

Study Types

2'-hydroxy-4-methoxychalcone

Cross-References

Synonyms (33)

Research Excerpts

Compound-Compound Interactions

Protein Targets (32)

Potency Measurements

Inhibition Measurements

Biological Processes (18)

Molecular Functions (10)

Ceullar Components (9)

Bioassays (66)

Research

Studies (27)

Market Indicators

Research Demand Index: 18.77

Study Types

Related Drugs (98)

Related Conditions (21)